Table 1.

CBD (cannabidiol) receptor interactions and their implications for neurological disorders [32].

Receptor target	Activity	Potential indications in neurological disorders
CB1 (cannabinoid receptor)	Partial agonist	Epilepsy, multiple sclerosis, Parkinson's disease
CB2 (cannabinoid receptor)	Agonist	Neuroinflammation, Alzheimer's disease, neuropathic pain
TRPV1	Agonist	Migraine, neuropathic pain, multiple sclerosis
5-HT1A	Agonist	Anxiety, depression, posttraumatic stress disorder (PTSD)
GPR55	Antagonist	Schizophrenia, neurodegenerative disorders
PPARγ	Agonist	Neuroinflammation, Alzheimer's disease, stroke
Glycine	Allosteric modulator	Spinal cord injury, epilepsy, neuropathic pain
Adenosine	Agonist	Sleep disorders, anxiety, epilepsy
GABA-A	Positive allosteric modulator	Anxiety, seizure disorders, insomnia
NMDA	Negative allosteric modulator	Alzheimer's disease, epilepsy, neurodegeneration
TRPM8	Agonist	Migraine, neuropathic pain, multiple sclerosis
P2X7	Antagonist	Neuroinflammation, multiple sclerosis, neuropathic pain
5-HT3	Antagonist	Nausea and vomiting, migraine, anxiety
D2	Partial agonist	Psychosis, schizophrenia, Parkinson's disease
FAAH	Inhibitor	Anxiety, depression, pain
TRPA1	Agonist	Migraine, neuropathic pain, multiple sclerosis
TRPV2	Agonist	Neuropathic pain, multiple sclerosis
P2Y12	Antagonist	Stroke, neuroinflammation, neurodegenerative disorders
5-HT2A	Antagonist	Depression, anxiety, posttraumatic stress disorder (PTSD)
CB1 and CB2	Modulation	Epilepsy, multiple sclerosis, Parkinson's disease

Abbreviation: FAAH: fatty acid amide hydrolase; GABAA: -aminobutyric acid type A receptor; GPR: G protein-coupled receptor; ND: not determined; 5-HT1A: serotonin receptor 1A; CB: cannabinoid receptor; PPAR-gamma: peroxisome proliferator-activated receptor; TRPM8: TRP channel of melastatin type 8; TRPV1: TRP channel of vanilloid type 1; TRPA1: TRP channel of ankyrin type 1.